Unternehmens-Profil
AstraZeneca PLC is a multinational pharmaceutical and biotechnology company headquartered at the Cambridge Biomedical Campus in Cambridge, United Kingdom. It focuses on researching, developing, manufacturing, and commercializing innovative medicines and vaccines across key therapeutic areas including oncology, biopharmaceuticals, cardiovascular, renal, metabolism, respiratory, immunology, rare diseases, and infection. The company maintains major research and development centers in Cambridge, UK; Gaithersburg, Maryland, US; Gothenburg, Sweden; and Warsaw, Poland, supporting a pipeline that addresses cancer, cardiovascular diseases, kidney diseases, influenza, and other conditions. AstraZeneca PLC delivers products for primary care, specialty care, and global health initiatives, with operations spanning innovative medicines and biologics. Its portfolio emphasizes treatments for respiratory inflammation, autoimmune disorders, gastrointestinal issues, neuroscience, and vaccines, contributing to advancements in non-communicable diseases and access programs in various regions worldwide. Founded in 1999, AstraZeneca PLC plays a significant role in the global biopharmaceutical market through its comprehensive therapeutic focus and strategic R&D investments.
Bewertungs-Kennzahlen
Allgemeine Finanzkennzahlen
Chart · 90 Tage
Letzter Kurs: 133,14 GBP· Stand 07.05.2026
News · AstraZeneca PLC
- 6 Pharma Dividend Stocks Yielding Up to 6.44% — and They've Survived Every Market Crash
- ABBV Stock Up 5% on Robust Q1 Performance: Time to Buy, Sell or Hold?
- The Most Important Part of These 3 Big Pharma Earnings Reports Wasn't the Beat
- AstraZeneca Prostate Drug Wins FDA Panel Backing As Breast Cancer Candidate Falters
- AstraZeneca stock falls after FDA panel votes against new cancer drug